Austria's medtech industry in healthy state of growth
This article was originally published in Clinica
Executive Summary
Austria's medtech market may be relatively small in a worldwide context, but it is solid and growing. And with its own points-based system of hospital reimbursement, the national healthcare system is not afraid to follow its own instincts rather than tread a worn path. But will its unique east-meets-west position now be under threat as the former Eastern bloc countries join the EU? Faraz Kermani found the answer to this and other questions on a recent visit to the national medical device industry association, Austromed
You may also be interested in...
China VBP, Localization And Other Strategies - How Far And Which Way?
Could health sector players encounter issues similar to those facing Tesla in China, a country which virtually saved the electric vehicle maker but where it is now facing challenges? Are there any lessons to be learned from a success story under China's volume-based procurement scheme? A partner at EY looks at these and other issues in an interview with Scrip.
Ratio Therapeutics On BMS Investment, Radiopharma R&D Trends, AI Use
The CEO and CSO of radiopharmaceutical company Ratio Therapeutics, which now has Bristol Myers Squibb as an investor, talk about Ratio’s R&D platforms, use of AI, an independent FAP-targeted asset and trends in radiopharma research such as combining other modalities like ADCs, in this podcast interview with Scrip
With One Launch Under Way, SpringWorks Ramps Up For A Second
The company initiated a rolling submission with the US FDA for mirdametinib, a MEK inhibitor that is poised to be its second commercial product for a rare disease.